Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 11/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9529240 | 0.85 | CA1 (0.41) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL26692823 | 0.85 | PI4KB (0.42) | CA1CA2LCKPI4KBATR | |
| SCHEMBL28733869 | 0.84 | LCK (0.39) | CA1CA2LCKPI4KBATR | |
| SCHEMBL31214081 | 0.82 | LCK (0.38) | CA1CA2LCKPI4KBATR | |
| SCHEMBL2174374 | 0.82 | LCK (0.52) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL15348877 | 0.82 | NPC1 (0.47) | CA1CA2LCKPI4KB | |
| SCHEMBL4135543 | 0.81 | LCK (0.37) | CA1CA2LCKPI4KB | |
| SCHEMBL23413609 | 0.81 | CA1 (0.44) | CA1CA2LCKPI4KBATR | |
| SCHEMBL1742407 | 0.81 | LCK (0.46) | CA1CA2LCKPI4KBATR | |
| SCHEMBL28733811 | 0.81 | CA1 (0.44) | CA1CA2LCKPI4KBATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| CN-113993587-A | Thiazole derivatives as protein secretion inhibitors | 科智生命科学公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | L3MBTL1 4610/4885CA1 4519/4885CA2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.